NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on

developing minimally disruptive surgical products and procedures for

the spine, announced today that the Company will participate in

several investor events in March 2012.

As part of its MedTech West Coast Bus Tour, Goldman Sachs will host a

group of investors at NuVasive's headquarters in San Diego, CA, on

Wednesday, March 7, 2012, at 11:15 a.m. PST.

Patrick F. Williams, Vice President of Strategy and Investor

Relations, is scheduled to present at the Barclays Capital Global

Healthcare Conference at the Loews Miami Hotel, Miami, FL, on Tuesday,

March 13, 2012, at 9:00 a.m. EST.

As part of its San Diego Medical Technology Bus Tour, Capstone

Investments will host a group of investors at NuVasive's headquarters

in San Diego, CA, on Thursday, March 22, 2012, at 10:30 a.m. PST.

A live webcast of each event will be available online from the

investor relations page of the Company's corporate website at

After the live webcast, a replay will remain available on the website

for 30 days.

About NuVasive NuVasive is a medical device company focused on

developing minimally disruptive surgical products and procedures for

the spine. The Company is the 5th largest player in the $7.7 billion

global spine market.

NuVasive's principal product offering is based on its Maximum Access

Surgery, or MAS@ platform. The MAS platform combines four categories

of products that collectively minimize soft tissue disruption during

spine surgery with maximum visualization and safe, easy

reproducibility for the surgeon: a proprietary software-driven nerve

avoidance system; MaXcess@, a unique split-blade retractor system; a

wide variety of specialized implants; and several biologic fusion

enhancers. MAS significantly reduces surgery time and returns patients

to activities of daily living much faster than conventional

approaches. Having redefined spine surgery with the MAS platform's

lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF@,

NuVasive has built an entire spine franchise. With over 65 products

today spanning lumbar, thoracic and cervical applications, the Company

will continue to expand and evolve its offering predicated on its R&D

focus and dedication to outstanding service levels supported by a

culture of Absolute Responsiveness@.

NuVasive cautions you that statements included in this press release

that are not a description of historical facts are forward-looking

statements that involve risks, uncertainties, assumptions and other

factors which, if they do not materialize or prove correct, could

cause NuVasive's results to differ materially from historical results

or those expressed or implied by such forward-looking statements. The

potential risks and uncertainties that could cause actual growth and

results to differ materially include, but are not limited to: the

uncertain process of seeking regulatory approval or clearance for

NuVasive's products or devices, including risks that such process

could be significantly delayed; the possibility that the FDA may

require significant changes to NuVasive's products or clinical

studies; the risk that products may not perform as intended and may

therefore not achieve commercial success; the risk that competitors

may develop superior products or may have a greater market position

enabling more successful commercialization; the risk that additional

clinical data may call into question the benefits of NuVasive's

products to patients, hospitals and surgeons; and other risks and

uncertainties more fully described in NuVasive's press releases and

periodic filings with the Securities and Exchange Commission.

NuVasive's public filings with the Securities and Exchange Commission

are available at

NuVasive assumes no obligation to update any forward-looking statement

to reflect events or circumstances arising after the date on which it

was made.